BioCardia (BCDA) Competitors $2.11 +0.12 (+6.03%) (As of 02:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainSEC FilingsShort InterestTrends BCDA vs. ENLV, FLGC, BGXX, MRNS, CARA, TENX, SYBX, APRE, TXMD, and MTEXShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Enlivex Therapeutics (ENLV), Flora Growth (FLGC), Bright Green (BGXX), Marinus Pharmaceuticals (MRNS), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Synlogic (SYBX), Aprea Therapeutics (APRE), TherapeuticsMD (TXMD), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Enlivex Therapeutics Flora Growth Bright Green Marinus Pharmaceuticals Cara Therapeutics Tenax Therapeutics Synlogic Aprea Therapeutics TherapeuticsMD Mannatech BioCardia (NASDAQ:BCDA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment. Which has stronger earnings & valuation, BCDA or ENLV? BioCardia has higher revenue and earnings than Enlivex Therapeutics. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$480K9.32-$11.57M-$4.19-0.50Enlivex TherapeuticsN/AN/A-$29.07M-$1.18-0.70 Does the MarketBeat Community favor BCDA or ENLV? Enlivex Therapeutics received 38 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 79.10% of users gave Enlivex Therapeutics an outperform vote while only 57.69% of users gave BioCardia an outperform vote. CompanyUnderperformOutperformBioCardiaOutperform Votes1557.69% Underperform Votes1142.31% Enlivex TherapeuticsOutperform Votes5379.10% Underperform Votes1420.90% Which has more risk & volatility, BCDA or ENLV? BioCardia has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Do analysts rate BCDA or ENLV? BioCardia presently has a consensus price target of $25.00, suggesting a potential upside of 1,084.83%. Enlivex Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 622.80%. Given BioCardia's higher probable upside, equities analysts clearly believe BioCardia is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is BCDA or ENLV more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to BioCardia's net margin of -1,999.77%. BioCardia's return on equity of 0.00% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets BioCardia-1,999.77% N/A -208.38% Enlivex Therapeutics N/A -71.76%-60.78% Does the media refer more to BCDA or ENLV? In the previous week, BioCardia had 6 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 9 mentions for BioCardia and 3 mentions for Enlivex Therapeutics. BioCardia's average media sentiment score of 0.81 beat Enlivex Therapeutics' score of 0.70 indicating that BioCardia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCardia 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enlivex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in BCDA or ENLV? 20.6% of BioCardia shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 20.0% of BioCardia shares are owned by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. SummaryBioCardia beats Enlivex Therapeutics on 10 of the 17 factors compared between the two stocks. Ad Darwin2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.31M$2.93B$5.07B$8.89BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-0.4815.0083.5712.93Price / Sales8.79280.711,220.3088.33Price / CashN/A168.0739.4636.25Price / Book1.534.696.936.25Net Income-$11.57M-$41.63M$119.12M$225.93M7 Day Performance-1.24%-4.73%-1.83%-1.32%1 Month Performance-25.75%-6.53%-3.64%0.60%1 Year Performance-78.94%25.63%31.64%26.23% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.0668 of 5 stars$2.11+6.0%$25.00+1,084.8%-81.6%$4.47M$480,000.00-0.5016Analyst RevisionGap UpENLVEnlivex Therapeutics3.075 of 5 stars$0.83-14.9%$6.00+622.8%-42.9%$17.77MN/A-0.7170News CoverageGap UpHigh Trading VolumeFLGCFlora Growth2.2015 of 5 stars$1.32+8.2%$6.00+354.4%+22.0%$17.65M$76.07M0.00280Analyst RevisionNews CoverageBGXXBright GreenN/A$0.09+5.4%N/A-78.4%$17.15MN/A-1.422News CoverageGap DownMRNSMarinus Pharmaceuticals4.4503 of 5 stars$0.31-0.3%$4.79+1,453.3%-95.0%$17.00M$30.99M-0.13110Analyst ForecastAnalyst RevisionGap DownCARACara Therapeutics3.7192 of 5 stars$0.30-0.2%$2.32+661.9%-71.2%$16.71M$20.97M-0.1855Analyst ForecastTENXTenax Therapeutics2.7706 of 5 stars$4.84+1.5%$16.00+230.6%-83.5%$16.50MN/A0.009Analyst RevisionNews CoveragePositive NewsSYBXSynlogic2.7524 of 5 stars$1.39-3.8%$30.00+2,058.3%-30.5%$16.26M$3.37M-0.356Positive NewsAPREAprea Therapeutics3.3831 of 5 stars$2.92-3.0%$15.50+430.8%-22.4%$15.86M$580,000.000.007Analyst ForecastAnalyst RevisionGap DownTXMDTherapeuticsMD0.6657 of 5 stars$1.37+2.4%N/A-54.1%$15.82M$1.30M0.00420Analyst ForecastMTEXMannatech0.936 of 5 stars$8.40+4.3%N/A-15.5%$15.79M$131.96M0.00250Analyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies ENLV Alternatives FLGC Alternatives BGXX Alternatives MRNS Alternatives CARA Alternatives TENX Alternatives SYBX Alternatives APRE Alternatives TXMD Alternatives MTEX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BCDA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
